RegenXBio ( (RGNX) ) has shared an update.
Mitchell Chan has been appointed as the new Executive Vice President and Chief Financial Officer of REGENXBIO Inc., a biotechnology firm at the forefront of gene therapy development. With nearly two decades of financial expertise in the healthcare sector, including a successful IPO and a $3 billion company acquisition under his belt, Chan is set to bring valuable experience as the company anticipates several crucial developments. He takes over from Vittal Vasista, who after over 15 years with the company, will continue to advise REGENXBIO to ensure a seamless transition.
For detailed information about RGNX stock, go to TipRanks’ Stock Analysis page.
